Moksifloksacin Pharmas (Moxifloxacin)

Moxifloxacin, the active ingredient in Moksifloksacin Pharmas, is a fluoroquinolone presented as an intravenous solution for intravenous use. It treats bacterial infections in adult patients. GNH USA supplies Moksifloksacin Pharmas as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals worldwide.

Moxifloxacin is a fluoroquinolone antibacterial used to manage a range of serious bacterial infections.

- Community‑acquired bacterial pneumonia: eradicates susceptible pathogens and improves clinical recovery. - Acute bacterial sinusitis: reduces bacterial load and relieves sinus inflammation. - Acute bacterial exacerbation of chronic bronchitis: shortens symptom duration and prevents complications. - Skin and skin‑structure infections: eliminates causative bacteria and promotes wound healing. - Intra‑abdominal infections: provides broad‑spectrum coverage for mixed aerobic and anaerobic organisms.

Moxifloxacin may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Nausea: mild to moderate upset stomach. - Diarrhea: loose stools, sometimes watery. - Headache: transient cranial discomfort. - Dizziness: sensation of light‑headedness. - Rash: mild skin erythema or itching. - Elevated liver enzymes: transient increase in hepatic transaminases.

Serious or Rare Side Effects: - Tendon rupture: especially Achilles tendon, may occur without warning. - QT interval prolongation: can precipitate ventricular arrhythmias. - Severe allergic reactions: anaphylaxis, angioedema, or Stevens‑Johnson syndrome. - Clostridioides difficile infection: colitis associated with antibiotic use. - Hepatic failure: rare but potentially life‑threatening liver injury. - Anaphylactic shock: immediate hypersensitivity requiring emergency care.

Before initiating therapy, consider patient‑specific factors and monitor for potential complications.

- Renal impairment: adjust dosing according to renal function and monitor creatinine. - Hepatic impairment: assess liver enzymes and use with caution in severe disease. - QT prolongation risk: avoid in patients with known cardiac arrhythmias or electrolyte disturbances. - Concurrent fluoroquinolone therapy: avoid to prevent additive toxicity. - Pregnancy and lactation: use only if the expected benefit justifies the potential risk. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze.

Moxifloxacin can interact with several drug classes, altering efficacy or safety.

Major Interactions (Avoid): - Other fluoroquinolones: increased risk of tendon toxicity and cumulative QT prolongation. - QT‑prolonging agents (e.g., macrolides, antiarrhythmics): heightened risk of serious cardiac arrhythmias. - Non‑steroidal anti‑inflammatory drugs (NSAIDs): may diminish antibacterial activity. - Warfarin: potentiates anticoagulant effect, requiring INR monitoring.

Moderate Interactions (Monitor Closely): - Corticosteroids: elevated risk of tendon rupture. - Theophylline: may raise plasma theophylline concentrations. - Cyclosporine: potential increase in moxifloxacin plasma levels. - Antacids containing aluminum or magnesium: can reduce absorption of oral formulations (less relevant for IV).